Blade therapeutics autotaxin
WebNov 8, 2024 · Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a noncompetitive autotaxin inhibitor and inhibitors of dimeric calpains designed for potential ... WebApr 4, 2024 · Blade Therapeutics, Inc. (“Blade” or “Company”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced receipt of feedback from the FDA regarding the company’s end-of-phase 1 data package for cudetaxestat, an investigational non …
Blade therapeutics autotaxin
Did you know?
WebMar 16, 2024 · Blade Therapeutics, Inc. is a biopharmaceutical company focused on developing cutting-edge treatments for debilitating, incurable fibrotic and neurodegenerative diseases that impact millions of ... WebApr 4, 2024 · Blade Therapeutics, Inc. today announced receipt of feedback from the FDA regarding the company’s end-of-phase 1 data package for cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for treatment of IPF and other fibrotic diseases.
WebJun 13, 2024 · Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains designed for the ... WebJan 7, 2024 · The company’s lead program is PAT-1251, a Phase 2 ready LOXL2 inhibitor, for the treatment of fibrotic diseases and some cancers. PharmAkea spun out PAT-409, …
WebSep 25, 2024 · Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc., including its core … WebLandos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune disease. …
WebOct 18, 2024 · Blade Therapeutics, Inc. (Blade or the company), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the initiation of a phase 1 drug-drug interaction clinical study of cudetaxestat, an investigational non-competitive autotaxin …
WebProvides specialty pharmaceutical and biopharmaceutical products, related services and targeted therapy management programs. Includes plans, resources and company … google assistant siri shortcutWebAccord Healthcare, Inc., the US subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company headquartered in Durham, North Carolina. Through its … google assistant shopping list appWebSep 20, 2024 · Blade is advancing a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and multiple inhibitors of dimeric calpains designed for potential ... chicago 13th ward officeWebSep 4, 2024 · Cudetaxestat (BLD-0409), which is Blade's lead investigational medicine, is a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is ... chicago 13 songsWebNov 8, 2024 · Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a noncompetitive autotaxin inhibitor and inhibitors of dimeric calpains designed for potential ... google assistant smart clockWebJun 13, 2024 · About Blade Therapeutics. Blade Therapeutics, Inc. is a biopharmaceutical company focused on developing cutting-edge treatments for debilitating, incurable fibrotic and neurodegenerative diseases ... chicago 13 tracklistWebAug 25, 2024 · Blade Therapeutics, Inc. is a biopharmaceutical company focused on developing cutting-edge treatments for fibrotic and neurodegenerative diseases that … google assistant smart display